Sodium metatungstate
Based on 11 publication(s) in Google Scholar
Sodium metatungstate (Sodium polyoxotungstate) is a NTPDase inhibitor, with Ki values of 2.58 μM, 3.26 μM, and 28.8 μM for NTPDase 1 (CD39), NTPDase 3 and NTPDase 2 respectively. Sodium metatungstate has anti-inflammatory and anti-cancer effect. Sodium metatungstate inhibits ATP breakdown but also blocks central synaptic transmission.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 93.4%
- CAS No.: 12141-67-2
- 화학식: H2Na6O40W12
- 분자량:2986.01
-
보관:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Blood Cancer Compound Library
HY-L079
-
Phosphatase Inhibitor Library
HY-L081
-
Angiogenesis-Related Compound Library
HY-L088
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cell Death Library
HY-L162
-
Ion Channel Compound Library
HY-L166
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Sodium metatungstate
More- Acta Pharm Sin B. 2025 May;15(5):2655-2672. [Abstract]
- J Nanobiotechnology. 2024 Jun 24;22(1):364. [Abstract]
- J Control Release. 2026 Mar 10:391:114632. [Abstract]
- ACS Appl Mater Interfaces. 2025 Aug 13;17(32):45382-45397. [Abstract]
- Int J Nanomedicine. 2025 Jan 27:20:1083-1100. [Abstract]
- Front Immunol. 2022 Nov 21:13:1026994. [Abstract]
- J Invest Dermatol. 2022 Apr;142(4):1065-1076.e19. [Abstract]
- Eur J Pharmacol. 2022 Feb 5:916:174729. [Abstract]
- Eur J Pharmacol. 2021 Aug 15:905:174198. [Abstract]
- Virol Sin. 2026 Mar 19:S1995-820X(26)00043-X. [Abstract]
- Clin Transl Immunology. 2024 Mar 18;13(3):e1499. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Flow Cytometry
-
Bio/Physico-chemical Assay
-
Flow Cytometry
All P2X Receptor Isoforms
MoreAll P2Y Receptor Isoforms
More
Biological Activity
|
IL-1β |
P2X7 Receptor |
Sodium metatungstate (100 μM, 15 min) inhibits the ATP-induced uptake of anionic dyes and the large ATP-induced channels in macrophage[2].
Sodium metatungstate (100 μM, 8 h) inhibits ATP-induced P2X7-associated pyroptosis in macrophage[2].
Sodium metatungstate (100 μM, 8-24 h) has a potent anti-inflammatory effect on macrophages[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Sodium metatungstate (5 mg/kg, Intraperitoneal injection, once per day from 0 to day 4, day 7-11, and day 14-18.) combine with anti-CD73 antibody and AZD4635(HY-101980) reduces tumor load in multiple myeloma (MM) mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Multiple myeloma (MM) mice developed by 3 weeks of injection of 5t33MM cells[4]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Had significantly lower spleen weights, fewer tumor cells in the spleen as well as significantly lower monoclonal immunoglobulin component level in circulation.
Chemical Information
-
CAS No. 12141-67-2
-
Appearance Solid
-
분자량 2986.01
-
화학식 H2Na6O40W12
-
Color White to off-white
-
SMILES
[3Na2WO4.9WO3]
-
Synonyms
Sodium polyoxotungstate; POM-1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
Metabolic reprogramming nanomedicine potentiates colon cancer sonodynamic immunotherapy by inhibiting the CD39/CD73/ADO pathway. [Abstract]2025 May;15(5):2655-2672. PMID: 40487643 -
J Nanobiotechnology
Potentiating dual-directional immunometabolic regulation with nanomedicine to enhance anti-tumor immunotherapy following incomplete photothermal ablation. [Abstract]2024 Jun 24;22(1):364. PMID: 38915007
Sodium metatungstate purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Jun 24;22(1):364. [Abstract]
FTIR spectra of Fe-PDAP, ICG, Sodium metatungstate (POM-1) and FIP.
Sodium metatungstate purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Jun 24;22(1):364. [Abstract]
The photothermal effect of FIP on cancer cells was assessed by flow cytometry. As expected, both FI and FIP displayed obvious cytotoxic toward 4T1 cells when subjected to 808 nm laser irradiation (1.5 W/cm-2, 10 min), suggesting that ICG is responsible for the photothermal killing effect rather than Sodium metatungstate (POM-1).
Sodium metatungstate purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Jun 24;22(1):364. [Abstract]
The Ade level of the FI + Laser group was significantly higher than the control group and FIP + Laser group at 6 h after laser irradiation, indicating the PTT could enhance the Ade generation and Sodium metatungstate (POM-1) could inhibit the Ade generation.
-
J Control Release
Single-fraction radiotherapy with a bioactive depot of CD39 blockade eradicates malignant tumors. [Abstract]2026 Mar 10:391:114632. PMID: 41539607 -
ACS Appl Mater Interfaces
Biomimetic Nanoparticles with Dual Targeting for Hepatocellular Carcinoma Promote Tumor Immune System Activation by Enhancing Extracellular ATP Homeostasis. [Abstract]2025 Aug 13;17(32):45382-45397. PMID: 40745694 -
Int J Nanomedicine
T Cell-Derived Apoptotic Extracellular Vesicles Ameliorate Bone Loss via CD39 and CD73-Mediated ATP Hydrolysis. [Abstract]2025 Jan 27:20:1083-1100. PMID: 39895982
Sodium metatungstate purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Jan 27:20:1083-1100. [Abstract]
ApoEVs hydrolyze ATP dose-dependently, which can be significantly mitigated by Sodium metatungstate (POM-1, 100 μM).
-
Front Immunol
Human gut microbiota-reactive DP8α regulatory T cells, signature and related emerging functions. [Abstract]2022 Nov 21:13:1026994. PMID: 36479125
Sodium metatungstate purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Nov 21:13:1026994. [Abstract]
CD3/CD28-stimulated VPD-stained CD4+ T cells were co-cultured with Treg clones (ratio 1:1) in the presence or not of CD39 and CD73 inhibitors, namely Sodium metatungstate (POM-1, 30 μM) and AB-680 (100 nM), respectively, as indicated. Proliferation was evaluated by VPD dilution.
-
J Invest Dermatol
CD39+ Fibroblasts Enhance Myofibroblast Activation by Promoting IL-11 Secretion in Hypertrophic Scars. [Abstract]2022 Apr;142(4):1065-1076.e19. PMID: 34537192 -
Eur J Pharmacol
2022 Feb 5:916:174729. PMID: 34973190 -
Eur J Pharmacol
CD39-mediated ATP-adenosine signalling promotes hepatic stellate cell activation and alcoholic liver disease. [Abstract]2021 Aug 15:905:174198. PMID: 34033815 -
Virol Sin
The expression of CD39 on NK cells relates to poor HIV-1 suppression in treatment-naïve HIV-1-infected individuals: Association with elevated IL-10 secretion and TIGIT co-expression. [Abstract]2026 Mar 19:S1995-820X(26)00043-X. PMID: 41864569 -
Clin Transl Immunology
CD39 expression defines exhausted CD4+ T cells associated with poor survival and immune evasion in human gastric cancer. [Abstract]2024 Mar 18;13(3):e1499. PMID: 38501063
용액&용해도
H2O : 50 mg/mL (16.74 mM; Need ultrasonic)
DMSO : 50 mg/mL (16.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (0.84 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (0.84 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (33.49 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
순도&문서
-
Data Sheet (277 KB)
-
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wall M J, et al. The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition [J]. Neuropharmacology, 2008, 55(7): 1251-1258. [Content Brief]
[2]. Pimenta-dos-Reis G, et al. POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages [J]. Purinergic Signalling, 2017, 13: 611-627. [Content Brief]
[3]. Csóka B, et al. CD39 improves survival in microbial sepsis by attenuating systemic inflammation [J]. The FASEB Journal, 2015, 29(1): 25. [Content Brief]
[4]. Yang R, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade [J]. Journal for immunotherapy of cancer, 2020, 8(1). [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.3349 mL | 1.6745 mL | 3.3490 mL | 8.3724 mL |
| 5 mM | 0.0670 mL | 0.3349 mL | 0.6698 mL | 1.6745 mL | |
| 10 mM | 0.0335 mL | 0.1674 mL | 0.3349 mL | 0.8372 mL | |
| 15 mM | 0.0223 mL | 0.1116 mL | 0.2233 mL | 0.5582 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Sodium metatungstate Related Classifications
HY-103259 Related Classifications
Powered by Bioz